Publications
5674 Results
- Journal / Conference
- Society for Neuro-Oncology Annual Meeting (SNO) (August 10-12, 2023, San Francisco, CA), poster
- Year
- 2023
- Research Committee(s)
- Brain
- Study Number(s)
- SWOG-9402
Higher vincristine doses correlate with longer overall survival: a post-hoc analysis of participants receiving PCV on RTOG 9402
- Journal / Conference
- JCO Oncol Pract 19, 2023 (suppl 11; abstr 368); ASCO Quality Care Symposium (October 27-28, 2023, Boston, MA), poster
- Year
- 2023
- Research Committee(s)
- Symptom Management and Survivorship
- Study Number(s)
- S2013
Examining patient uptake of electronic patient-reported outcomes (ePRO) in a prospective clinical study of immune-related adverse events (IR-AEs)
- Journal / Conference
- Journal of Molecular Diagnotics Volume 25;Issue 11, SupplementS1-S186; Association for Molecular Pathology (AMP) 2023 Conference (Nov 14-18, 2023, Salt Lake City, UT), poster
- Year
- 2023
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0106
Whole Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid Leukemia (SWOG S0106)
- Journal / Conference
- Annals of Oncology VOLUME 34, SUPPLEMENT 2, S1292; ESMO (October 20-24, 2023, Madrid, Spain), proferred paper presentation
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/A021602
Alliance A021602: Phase III, Double Blinded Study of Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET) After Progression on Prior Therapy (CABINET)
- Journal / Conference
- IKCS North America (Nov 9-11, 2023, Nashville, TN), TIP poster
- Year
- 2023
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S2200
PAPMET2 A Phase II Randomized Trial of Cabozantinib with or without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma (PRCC): SWOG S2200)
- Journal / Conference
- ASH Annual Meeting (Dec9-12,2023, San Diego, CA), oral
- Year
- 2023
- Research Committee(s)
- Myeloma
- Study Number(s)
- S0777, S1211
Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211
- Journal / Conference
- IWCLL (October 6-9, 2023, Boston, MA), TIP poster
- Year
- 2023
- Research Committee(s)
- Leukemia
- Study Number(s)
- S1925
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study (SWOG S1925; NCT#04269902)
- Journal / Conference
- Gastroenterology Jan 18:S0016-5085(24)00049-0. doi: 10.1053/j.gastro.2024.01.013. Online ahead of print
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID38244727
- Study Number(s)
- S1505
Intra-tumoral cell neighborhoods coordinate outcomes in pancreatic ductal adenocarcinoma
- Journal / Conference
- JCO Oncol Pract Oct;19(10):907-916
- Year
- 2023
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID37643386
- PMC
- PMC10615547
Sponsors’ Perspectives on the Impact of the COVID-19 Public Health Emergency on Interventional Cancer Clinical Trial Protocols and Data Quality
- Journal / Conference
- JCO Clinical Cancer Informatics Sep;7:e2300116. doi: 10.1200/CCI.23.00116
- Year
- 2023
- Research Committee(s)
- Breast
- PMID
- PMID38011617
- PMC
- PMC10703127
- Study Number(s)
- S0307